Novel Therapeutics Targeting Epigenetics: New Molecules, New Methods.

S. Frye,Jian Jin

DOI: https://doi.org/10.1021/acsmedchemlett.6b00037

2016-02-11

ACS Medicinal Chemistry Letters

Abstract:Methods T scientific community’s interest in epigenetic regulation and medicinal chemists’ ability to design potent and selective small molecule probes and drug leads have intersected in an exciting and productive fashion over the last five years resulting in rapid translation of epigenetic therapeutic hypotheses to clinical interventions. While inhibitors of druggable enzyme targets such as the protein lysine methyltransferases, EZH2 and DOT1L, have followed on the heels of histone deacetylases inhibitors (HDACs) in pioneering clinical studies of small molecules that regulate histone posttranslational modifications, small molecule antagonists of the readers of acetyl-lysine (Kac, bromodomains) are perhaps the poster child for the “probe-to-biology-to-drug” revolution in the field of chromatin regulation. In a period of less than 5 years, chemical probes for bromodomains were described, their ability to regulate the c-Myc oncogene defined, and large pharmaceutical companies invested significantly in drug development in this area. The critical insight that the “undruggable” transcription factor and oncogene, c-Myc, could be modulated in a therapeutically useful fashion was driven by the activity of the initial chemical probes, JQ1 and IBET. In addition to this translational impact, examination of the mechanism of c-Myc modulation led to a fundamentally new concept in chromatin regulation−the existence of superenhancer sites that are uniquely responsive to disruption of BRD4 bromodomain recognition of Kac. With this backdrop, it is a great pleasure to introduce the Special Issue, “Novel Therapeutics Targeting Epigenetics”, which includes contributions from ACS Medicinal Chemistry Letters, Journal of Medicinal Chemistry, ACS Chemical Biology, and Biochemistry. We were excited to see the variety of targets explored in the manuscripts submitted: novel methyltransferases (PRMT5, SMYD3), progress in small molecule ligands for methyl lysine readers (CBX6), new assay technology for DNA hydroxylase (Tet1), and discussion of target class screening considerations for hit discovery. Progress in the field of Epigenetic drug discovery is accelerating, and this special issue captures some of the most important breaking stories in this exciting area. We would like to thank our authors for their many outstanding contributions. We also thank the numerous reviewers who carefully evaluated these manuscripts. Special thanks go to the Editors of ACS Medicinal Chemistry Letters and the editorial office staff for their continuous support of this project. Last but not least, we very much hope that the readers of ACS Medicinal Chemistry Letters will enjoy this Special Issue on Novel Therapeutics Targeting Epigenetics. Stephen V. Frye Chemical Biology and Medicinal Chemistry, UNC Chapel Hill Jian Jin Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai ■ AUTHOR INFORMATION Notes Views expressed in this editorial are those of the author and not necessarily the views of the ACS.